AVS100
Locally advanced or metastatic solid tumors
Phase 1Active
Key Facts
Indication
Locally advanced or metastatic solid tumors
Phase
Phase 1
Status
Active
Company
About Avstera Therapeutics
Avstera Therapeutics is a private, clinical-stage biotech founded in 2018, focusing on oral small molecule therapies targeting RNA-binding proteins and HDAC6 for immuno-oncology and other diseases. Its lead asset, AVS100, is an IND-cleared, highly selective oral HDAC6 inhibitor for solid tumors, with a preclinical pipeline extending into cardiometabolic indications. The company is led by founder-CEO Karthik Musunuri and co-founder Ajay Raju, leveraging a foundation in immunology and strategic residency at J&J JLABS to advance its programs.
View full company profileTherapeutic Areas
Other Locally advanced or metastatic solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| Systemic DNase I | Xenetic Biosciences | Preclinical |
| BC3195 | BioCity Biopharma | Phase 1 |
| UGN-401 | UroGen Pharma | Phase 1/2 |